在赛诺菲公布这项投资计划之际，中国政府正努力吸引外国公司扩大在华业务。包括阿斯利康(AZN.US)和罗氏在内的跨国制药商采取了“在中国，为中国”(In China，For China )的战略，以服务日益增长的中国医药市场。在地缘政治紧张局势威胁到药品和疫苗生产的背景下，制药行业的交易是中国与西方国家之间一个不同寻常的亮点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.